GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » 1-Year ROIIC %

Atreca (Atreca) 1-Year ROIIC % : -34.31% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Atreca 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Atreca's 1-Year ROIIC % for the quarter that ended in Sep. 2023 was -34.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Atreca's 1-Year ROIIC % or its related term are showing as below:

BCEL's 1-Year ROIIC % is ranked worse than
60.52% of 1474 companies
in the Biotechnology industry
Industry Median: -4.265 vs BCEL: -34.31

Atreca 1-Year ROIIC % Historical Data

The historical data trend for Atreca's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca 1-Year ROIIC % Chart

Atreca Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
1-Year ROIIC %
Get a 7-Day Free Trial -680.66 -192.15 -304.99 -39.13 1,073.10

Atreca Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.97 1,073.10 -105.08 -352.00 -34.31

Competitive Comparison of Atreca's 1-Year ROIIC %

For the Biotechnology subindustry, Atreca's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atreca's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Atreca's 1-Year ROIIC % falls into.



Atreca 1-Year ROIIC % Calculation

Atreca's 1-Year ROIIC % for the quarter that ended in Sep. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -78.377 (Sep. 2023) - -106.502 (Sep. 2022) )/( 4.032 (Sep. 2023) - 86.005 (Sep. 2022) )
=28.125/-81.973
=-34.31%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Atreca  (OTCPK:BCEL) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Atreca 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Atreca's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atreca (Atreca) Business Description

Traded in Other Exchanges
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Executives
Felix Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz officer: VP of Finance C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould officer: Chief Scientific Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini director, officer: Chief Strategy Officer C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney officer: General Counsel & Secretary ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop officer: Chief Medical Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma director C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg officer: Chief Scientific Officer 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson director 500 SAGINAW DRIVE, REDWOOD CITY CA 94063

Atreca (Atreca) Headlines

From GuruFocus

Atreca Announces Corporate Reorganization to Extend Cash Runway

By GuruFocusNews GuruFocusNews 06-11-2022

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

By GuruFocusNews GuruFocusNews 07-06-2022

Atreca to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-07-2022

Atreca to Present at Upcoming Investor Conferences

By PurpleRose PurpleRose 08-02-2022

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

By GuruFocusNews GuruFocusNews 06-26-2022

BAKER BROS. ADVISORS LP Reduces Stake in Atreca Inc

By GuruFocus Research 10-24-2023

Atreca to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-18-2022